β The Problem
Muscle Loss Is Silently Epidemic β And Partly Written in Your Genes
Every decade after 30, adults lose 3β8% of their muscle mass β and the rate accelerates sharply after 60. Sarcopenia is when this loss becomes clinically dangerous: increasing fall risk, hospitalization, and loss of independence. Twin studies prove genetics accounts for 46β76% of muscle mass variation, yet the specific genes responsible in Middle Eastern populations had never been identified.
Muscle Lost Per Decade After 50
0%
That's up to 15% less muscle each decade in sarcopenic individuals β comparable to years of aging compressed into months of disease.
How Much Is Genetic?
Heritability estimates from longitudinal twin studies
π Muscle Mass Decline With Age (Schematic)
23%
Elderly Iranian Men Affected
(BEH cohort)
24%
Elderly Iranian Women Affected
(BEH cohort)
~ΒΌ
Proportion facing disability risk
if untreated
π§¬
Genetic Risk
IL10 variants disrupt muscle inflammation balance
π
Sarcopenia
Accelerated loss of muscle mass & strength
π€
Falls & Fractures
3Γ higher fall risk in sarcopenic elderly
π₯
Hospitalization
Loss of independence, higher mortality
β‘ The Data
Real Elderly Iranians, Real Genome-Scale Data
The Bushehr Elderly Health (BEH) cohort β one of Iran's most comprehensive aging studies β provided 2,772 participants aged 60+, each with full genome genotyping and two clinical muscle measurements taken on the same visit day. This rare combination of genomic + phenotypic data in a non-European population makes the findings both statistically robust and globally significant.
2,772
Eligible participants aged 60+ with complete genetic & phenotypic data
52%
Female participants avg 69.6 yrs
663K
SNPs genotyped per person
69.2
Mean age overall (years)
r=.52
SMIβHandgrip correlation
Participant Age Distribution (BEH Cohort)
SMI β Handgrip Strength Correlation
r = 0.52 (p < 0.001)
This strong positive correlation is the statistical justification for the joint model β if two outcomes share genetic drivers, testing them together dramatically increases power to detect those drivers.
Two measurements per participant: Skeletal Muscle Index (SMI) β low defined as <7.0 kg/mΒ² (men) / <5.4 kg/mΒ² (women) β and Handgrip Strength β low at <26 kg (men) / <18 kg (women). Their shared genetic basis is exactly why the multivariate approach was chosen.
β’ The Method
Why Two Traits Together Beats One at a Time
Standard genetic studies test one trait at a time. But sarcopenia has two defining symptoms β low muscle mass AND low grip strength. This study uses MultiPhen, a method that tests both simultaneously, then confirms findings gene-wide using GATES. The result: more statistical power, fewer missed signals.
π
Conventional Approach
Run GWAS on muscle mass alone. Then run a second GWAS on grip strength alone. Compare two separate lists of p-values. Shared genetic signals get diluted. Multiple testing burden increases.
β Lower Statistical Power
π
MultiPhen + GATES
Regress genotype on both outcomes simultaneously using ordinal regression. One joint p-value per SNP. Then aggregate all SNPs via GATES for a single gene-level confirmation.
β Up to 2Γ More Powerful
Simulated Statistical Power: Joint vs. Single-Trait Tests
π§¬
Select Gene
Focus on IL10 gene on chromosome 1. Extract 663K+ variants within Β±50kb flanking region.
π
MultiPhen Test
Joint ordinal regression of each SNP against both SMI and grip strength simultaneously.
π
LD Filtering
Keep only independent SNPs (rΒ² β€ 0.4, MAF > 0.01, HWE p > 0.05) β 27 variants.
β
GATES Confirm
Aggregate all 27 SNP p-values into a single gene-level score via Extended Simes procedure.
β Gene Selection
- IL10 Β· Chromosome 1
- Position: 206,940,947β206,945,839
- Β±50 kb flanking region
- 445,034 variants screened
β‘ MultiPhen
- Ordinal regression on genotype
- Both SMI + handgrip as inputs
- Additive model (0/1/2 alleles)
- Likelihood ratio test per SNP
β’ LD Filter
- rΒ² β€ 0.4 threshold
- MAF > 0.01 retained
- HWE p-value > 0.05
- 27 independent SNPs kept
β£ GATES
- Gene-based aggregation
- Extended Simes procedure
- Accounts for SNP correlation
- Single gene-level p-value
β£ Results
IL10 Confirmed β Three Significant Variants, One Gene
Out of 27 candidate variants on the IL10 gene, three intronic variants reached significance in the joint MultiPhen model. The GATES gene-level aggregation confirmed IL10 as a whole (p = 0.046) β the first such confirmation in an Iranian population and one that validates the inflammatory pathway hypothesis at genomic scale.
3
Significant IL10 variants (MultiPhen p < 0.05)
rs11119603 Β· rs3950619 Β· rs57461190
0.046
IL10 gene-level p-value (GATES)
below 5% significance threshold
0.88
Largest effect size observed (rs3950619)
range: 0.178 β 0.883
SNP Significance Across IL10 β Manhattan-Style View (βlogββ p-value)
Effect Sizes of Significant IL10 Variants with p-Values
| SNP | Chr | Risk Allele | MAF | Effect Size | p-value | Status |
|---|
| rs11119603 | 1 | C | 0.292 | 0.178 | 0.00384 | Significant |
| rs3950619 | 1 | C | 0.442 | 0.883 | 0.03641 | Significant |
| rs57461190 | 1 | T | 0.292 | 0.221 | 0.00411 | Significant |
| rs12042283 | 1 | C | 0.488 | β | 0.277 | Not significant |
| rs1800871 | 1 | A | 0.266 | β | 0.858 | Not significant |
| Β· Β· Β· 22 additional non-significant SNPs not shown Β· Β· Β· |
π¬
The Biology: Why IL10 Drives Muscle Loss
IL10 (Interleukin-10) is your body's anti-inflammatory "off switch." When muscles age, pro-inflammatory signals (IL-6) accelerate protein breakdown. IL10 tries to suppress this β but genetic variants in IL10 can weaken this protection, letting inflammation damage muscle unchecked. This study proves that genetic variation in IL10 is one of the keys controlling how fast your muscles age.
π§¬
IL10 Variants
rs11119603, rs3950619, rs57461190 disrupt function
β
β‘
Reduced IL10 Activity
Anti-inflammatory brake weakens; IL-6 goes unchecked
β
πͺ
Muscle Breakdown
Chronic inflammation accelerates sarcopenia onset
β€ Takeaways
What This Means Beyond the Numbers
01
Joint Testing Is More Powerful
MultiPhen caught signals that single-trait GWAS would have missed. The lesson extends across all multi-symptom diseases: correlated outcomes should always be tested together.
02
IL10 Confirmed as Risk Gene in Iran
GATES p = 0.046 validates what cell biology suggested. This is the first genomic confirmation in an Iranian cohort β filling a critical gap in non-European genetic data.
03
Genomics Needs Diverse Populations
Most GWAS studies are 80%+ European. This BEH cohort analysis proves that Middle Eastern populations harbour important genetic signals overlooked by existing literature.
04
Gateway to Early Screening
Knowing your IL10 genotype could flag sarcopenia risk decades early β enabling targeted nutrition, exercise, and pharmacological interventions before irreversible muscle loss begins.